Klinične študije:
*Favari L, Perez-Alvarez V. Departamento de Farmacología y Toxicología, Centro de Investigación y de Estudios avanzados del IPN, México, D.F. Comparative effects of colchicine and silymarin on CCl4- chronic liver damage in rats. Arch Med Res. 1997 Spring;28(1):11-7. PMID: 9078581 [PubMed-indexed for MEDLINE].
*Leng-Peschlow E., Madaus AG, Ostmerheimer Str. 198, D-51109
*Koln Germany (United Kingdom). Properties and Medical Use of Flavonolignans (Silymarin) from Silybum marianum. Phytotherapy Research, Vol. 10, S25-S26 (1996).
Bean P. Rogers Memorial Hospital, Oconomowac, WI, USA. The use of alternative medicine in the treatment of hepatitis C. Am Clin Lab. 2002 May;21(4):19-21. PMID: 12087634 [PubMed-indexed for MEDLINE].
*Reliable phytotherapy in chronic liver diseases. Therapiewochen (Germany), 1996, 46/17 (916+918-919).
*Mourelle M, Muriel P, Favari L, Franco T.Pharmacology and Toxicology Department, Cinvestav-I.P.N., Mexico. Prevention of CCL4- induced liver cirrhosis by silymarin. Fundam Clin Pharmacol. 1989;3(3):183-91. PMID: 2548940 [PubMed-indexed for MEDLINE].
*Lapis K, Jeney A, Divald A, Vajta G, Zalatnai A, Schaff Z. Institute of Pathology and Experimental Cancer Research, Semmelweis Medical University, Budapest, Hungary. Experimental studies on the effect of hepatoprotective compounds. Tokai J Exp Clin Med. 1986;11 Suppl:135-PMID: 3330627 [PubMed-indexed for MEDLINE].
*Feher J, Lang I, Deak G, Cornides A, Nekam K, Gergely P. Department of Medicine, Semmelweis University, Budapest, Hungary. Free radicals in tissue damage in liver diseases and therapeutic approach. Tokai J Exp Clin Med. 1986;11 Suppl:121-34. PMID: 3452238 [PubMed-indexed for MEDLINE].
*Flora K, Hahn M, Rosen H, Benner K. Division of Gastroenterology, Oregon Health Sciences University, Portland 97201-3098, USA. Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol. 1998 Feb;93(2):139-43. PMID: 9468229 [PubMed-indexed for MEDLINE].
* Salmi HA, Sarna S. Effect of silymarin on chemical, functional, and morphological alterations of the liver. A double-blind controlled study. Scand J Gastroenterol. 1982 Jun;17(4):517-21. PMID: 6753109 [PubMed-indexed for MEDLINE].
*Valenzuela A, Lagos C, Schmidt K, Videla LA. Silymarin protection against hepatic lipid peroxidation induced by acute ethanol intoxication in the rat. Biochem Pharmacol. 1985 Jun 15;34(12):2209-12. PMID: 4039940 [PubMed-indexed for MEDLINE].
*Tedesco D, Domeneghini C, Sciannimanico D, Tameni M, Steidler S, Galletti S. Department of Veterinary Science and Technology for Food Safety, Faculty of Veterinary Medicine, University of Milan, Via Celoria 10, 20133, Milan, Italy. Silymarin, a possible hepatoprotector in dairy cows: biochemical and histological observations. J Vet Med A Physiol Pathol Clin Med. 2004 Mar;51(2):85-9. PMID: 15153078 [PubMed-in process].
*Schumann J, Prockl J, Kiemer AK, Vollmar AM, Bang R, Tiegs G. Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nuremberg, Fahrstrasse 17, DE-91054 Erlangen, Germany. Silibinin protects mice from T cell-dependent liver injury. J Hepatol. 2003 Sep;39(3):333-40. PMID: 12927918 [PubMed-indexed for MEDLINE].
*Ram VJ. Medicinal Chemistry Division, Central Drug Research Institute, Lucknow, India. Herbal preparations as a source of hepatoprotective agents. Drug News Perspect. 2001 Aug;14(6):353-63. PMID: 12813598 [PubMed].
*Ahmed B, Khan SA, Alam T. Antihepatotoxic Research Laboratory, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Jamia Hamdard, Hamdard Nagar, New Delhi, India. Synthesis and antihepatotoxic activity of some heterocyclic compounds containing the 1,4-dioxane ring system. Pharmazie. 2003 Mar;58(3):173-6. PMID: 12685811 [PubMed-indexed for MEDLINE].
*Dvorak Z, Kosina P, Walterova D, Simanek V, Bachleda P, Ulrichova J. Institute of Medical Chemistry and Biochemistry, Faculty of Medicine, Palacky University Hnevotinska 3, 775 15 Olomouc, Czech Republic. Primary cultures of human hepatocytes as a tool in cytotoxicity studies: cell protection against model toxins by flavonolignans obtained from Silybum marianum. Toxicol Lett. 2003 Feb 3;137(3):201-12. PMID: 12523963 [PubMed-indexed for MEDLINE].
*Lang I, Nekam K, Deak G, Muzes G, Gonzales-Cabello R, Gergely P, Csomos G, Feher J. Second Department of Medicine, Semmelweis University Medical School, Budapest, Hungary. Immunomodulatory and hepatoprotective effects of in vivo treatment with free radical scavengers. Ital J Gastroenterol. 1990 Oct;22(5):283-7. PMID: 1983711 [PubMed-indexed for MEDLINE].
*Jacobs BP, Dennehy C, Ramirez G, Sapp J, Lawrence VA. Department of Medicine, University of California, San Francisco 94143, USA. Milk thistle for the treatment of liver disease: a systematic review and meta-analysis. Am J Med. 2002 Oct 15;113(6):506-15. PMID: 2427501 [PubMed-indexed for MEDLINE].
*Fiebig M, Wagner H. New antihepatotoxic effects of flavonolignans of a white flowering variety of Silybum. Planta Med. 1984 Aug;50(4):310-3. PMID: 6095354 [PubMed-indexed for MEDLINE].
*Fintelmann V. Medizinische Abteilung B, Krankenhaus Rissen, Hamburg, Federal Republic of Germany. Modern phytotherapy and its uses in gastrointestinal conditions. Planta Med. 1991 Oct;57(7):S48-52. PMID: 1956958 [PubMed-indexed for MEDLINE].
*Piscitelli SC, Formentini E, Burstein AH, Alfaro R, Jagannatha S, Falloon J. Department of Pharmacy, National Institutes of Health, Bethesda, Maryland 20892-1880, USA. Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. Pharmacotherapy. 2002 May;22(5):551-6. PMID: 12013352 [PubMed-indexed for MEDLINE].
*Saller R, Meier R, Brignoli R. Abteilung Naturheilkunde, University Hospital Zurich, Switzerland. The use of silymarin in the treatment of liver diseases. Drugs. 2001;61(14):2035-63. PMID: 11735632 [PubMed- indexed for MEDLINE].
*Hernandez V. Direct AIDS Alternative Information Resources, New York, NY. Liver function and HIV-1 infection. STEP Perspect. 1995 Summer;7(2):13-5. PMID: 11362718 [PubMed-indexed for MEDLINE].
*Venkataramanan R, Ramachandran V, Komoroski BJ, Zhang S, Schiff PL, Strom SC. Department of Pharmaceutical Sciences School of Pharmacy, Pennsylvania, USA. Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. Drug Metab Dispos. 2000 Nov;28(11):1270-3. PMID: 11038151 [PubMed-indexed for MEDLINE].
*Luper S. Southwest College of Naturopathic Medicine: 2140 East Broadway Rd. Tempe, AZ 85282, USA. A review of plants used in the treatment of liver disease: part 1. Altern Med Rev. 1998 Dec;3(6):410-21. PMID: 9855566 [PubMed-indexed for MEDLINE].
*Rumiantseva ZhN. The pharmacodynamics of hepatic protectors from the lady’s-thistle (Silybum marianum). Vrach Delo. 1991 May;(5):15-PMID: 1866906 [PubMed-indexed for MEDLINE].
*Hikino H, Kiso Y, Wagner H, Fiebig M. Antihepatotoxic actions of flavonolignans from Silybum marianum fruits. Planta Med. 1984 Jun;50(3):248-50. PMID: 6091165 [PubMed-indexed for MEDLINE].
*Schriewer H, Weinhold F. The influence of silybin from Silybum marianum (L.) Gaertn. on in vitro phosphatidyl choline biosynthesis in rat livers. Arzneimittelforschung. 1979;29(5):791-2. PMID: 582978 [PubMed- indexed for MEDLINE].Schriewer H, Kramer U, Rutkowski G, Borgis KJ. Influence of Silybin-dihemisuccinate on fatty acid synthesis in rat liver (author’s transl). Arzneimittelforschung. 1979;29(3):524-6. PMID: 39576 [PubMed-indexed for MEDLINE.
*De Martiis M, Fontana M, Assogna G, D’Ottavi R, D’Ottavi O. Milk thistle (Silybum marianum) derivatives in the therapy of chronic hepatopathies. Clin Ter. 1980 Aug 15;94(3):283-315. PMID: 7004762 [PubMed-indexed for MEDLINE].
*Parasassi T, Martellucci A, Conti F, Messina B. Drug-membrane interactions: silymarin, silibyn and microsomal membranes. Cell Biochem Funct. 1984 Apr;2(2):85-8. PMID: 6467519 [PubMed-indexed for MEDLINE].
*Giese LA. Complementary healthcare practices. Gastroenterol Nurs. 2001 Jan-Feb;24(1):38-40. PMID: 11847721 [PubMed-indexed for MEDLINE].
*Wu DF, Peng RX, Ye LP, Yu P. Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei, China. The effects of silymarin on hepatic microsomal and mitochondrial membrane fluidity in mice. Zhongguo Zhong Yao Za Zhi. 2003 Sep;28(9):870-2. PMID: 15015386 [PubMed-in process].
*Joyeux M, Rolland A, Fleurentin J, Mortier F, Dorfman P. Centre des Sciences de l’Environnement, Universite de Metz, France. Tert-Butyl hydroperoxide-induced injury in isolated rat hepatocytes: a model for studying anti-hepatotoxic crude drugs. Planta Med. 1990 Apr;56(2):171-4. PMID: 2353064 [PubMed-indexed for MEDLINE].
*Muzes G, Deak G, Lang I, Nekam K, Gergely P, Feher J. Department of Medicine, Semmelweis University, Budapest, Hungary. Effect of the bioflavonoid silymarin on the in vitro activity and expression of superoxide dismutase (SOD) enzyme. Acta Physiol Hung. 1991;78(1):3-9. PMID: 1763650 [PubMed – indexed for MEDLINE]
*Lirussi F, Okolicsanyi L. Institute of Internal Medicine, University of Padua, Italy. Cytoprotection in the nineties: experience with ursodeoxycholic acid and silymarin in chronic liver disease. Acta Physiol Hung. 1992;80(1-4):363-7. PMID: 1345202 [PubMed-indexed for MEDLINE].
*Feher J, Cornides A, Pal J, Lang I, Csomos G. 2nd Department of Medicine, Semmelweis University, Budapest, Hungary. Liver cell protection in toxic liver lesion. Acta Physiol Hung. 1989;73(2-3):285-91. PMID: 2596318 [PubMed-indexed for MEDLINE].
*Feher J, Deak G, Muzes G, Lang I, Niederland V, Nekam K, Karteszi M. Liver-protective action of silymarin therapy in chronic alcoholic liver diseases. Orv Hetil. 1989 Dec 17;130(51):2723-7. PMID: 2574842 [PubMed-indexed for MEDLINE].
*Giese LA. Milk thistle and the treatment of hepatitis. Gastroenterol Nurs. 2001 Mar-Apr;24(2):95-7. PMID: 11847735 [PubMed-indexed for MEDLINE].
*Tanasescu C, Petrea S, Baldescu R, Macarie E, Chiriloiu C, Purice S. N. Gh. Lupu Institute of Internal Medicine, Bucharest, Romania. Use of the Romanian product Silimarina in the treatment of chronic liver diseases. Med Interne. 1988 Oct-Dec;26(4):311-22. PMID: 3072661 [PubMed-indexed for MEDLINE].
*Buzzelli G, Moscarella S, Giusti A, Duchini A, Marena C, Lampertico M. Istituto di Clinica Medica II, Universita degli Studi di Firenze, Italy. A pilot study on the liver protective effect of silybin- phosphatidylcholine complex (IdB1016) in chronic active hepatitis. Int J Clin Pharmacol Ther Toxicol. 1993 Sep;31(9):456-60. PMID: 8225695 [PubMed-indexed for MEDLINE].
*Par A, Roth E, Rumi G Jr, Kovacs Z, Nemes J, Mozsik G. Pecsi Tudomanyegyetem, Altalanos Orvostudomanyi Kar, I. Belgyogyaszati Klinika. Oxidative stress and antioxidant defense in alcoholic liver disease and chronic hepatitis C. Orv Hetil. 2000 Jul 23;141(30):1655-9. PMID: 10962902 [PubMed-indexed for MEDLINE].
*Shimizu I. Second Department of Internal Medicine, Tokushima University School of Medicine, Tokushima, Japan. Antifibrogenic therapies in chronic HCV infection. Curr Drug Targets Infect Disord. 2001 Aug;1(2):227-40. PMID: 12455417 [PubMed-indexed for MEDLINE].
*Berkson BM. Integrative Medical Center of New Mexico, New Mexico State University, Las Cruces, USA. A conservative triple antioxidant approach to the treatment of hepatitis C. Combination of alpha lipoic acid (thioctic acid), silymarin, and selenium: three case histories. Med Klin (Munich). 1999 Oct 15;94 Suppl 3:84-9. PMID: 10554539 [PubMed-indexed for MEDLINE].
*Patrick L. Hepatitis C: epidemiology and review of complementary/alternative medicine treatments. Altern Med Rev. 1999 Aug;4(4):220-38. PMID: 10468647 [PubMed-indexed for MEDLINE].
*Magliulo E, Gagliardi B, Fiori GP. Results of a double blind study on the effect of silymarin in the treatment of acute viral hepatitis, carried out at two medical centres (author’s transl). Med Klin. 1978 Jul 14;73(28-29):1060-5. PMID: 353464 [PubMed-indexed for MEDLINE].
*Trinchet JC, Coste T, Levy VG, Vivet F, Duchatelle V, Legendre C, Gotheil C, Beaugrand M. Services d’Hepato-Gastroenterologie et d’Anatomopathologie, Hopital Jean Verdier, Bondy. Treatment of alcoholic hepatitis with silymarin. A double-blind comparative study in 116 patients. Gastroenterol Clin Biol. 1989;13(2):120-4. PMID: 2707520 [PubMed-indexed for MEDLINE].
* Bode JC, Schmidt U, Durr HK. Silymarin for the treatment of acute viral hepatitis? Report of a controlled trial (author’s transl). Med Klin. 1977 Mar 25;72(12):513-8. PMID: 840125 [PubMed-indexed for MEDLINE].
*Ferenci P, Dragosics B, Dittrich H, Frank H, Benda L, Lochs H, Meryn S, Base W, Schneider B. 1st Department of Gastroenterology and Hepatology, University of Vienna, Austria. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol. 1989 Jul;9(1):105-13. PMID: 2671116 [PubMed-indexed for MEDLINE].
*Lieber CS. Section of Liver Disease and Nutrition, Bronx VA Medical Center and Mt. Sinai School of Medicine, (151-2), 130 West Kingsbridge Road, Bronx, NY 10468, USA. New concepts of the pathogenesis of alcoholic liver disease lead to novel treatments. Curr Gastroenterol Rep. 2004 Feb;6(1):60-5. PMID: 14720455 [PubMed- indexed for MEDLINE].
*Lieber CS, Leo MA, Cao Q, Ren C, DeCarli LM. Section of Liver Disease & Nutrition, Bronx VA Medical Center & Mount Sinai School of Medicine, Bronx, New York 10468, USA. Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons. J Clin Gastroenterol. 2003 Oct;37(4):336-9. PMID: 14506392 [PubMed-indexed for MEDLINE].
*Muriel P, Moreno MG. Section of Pharmacology, Cinvestav-IPN, Mexico 07000, DF, Mexico. Effects of silymarin and vitamins E and C on liver damage induced by prolonged biliary obstruction in the rat. Basic Clin Pharmacol Toxicol. 2004 Feb;94(2):99-104. PMID: 14748853 [PubMed-indexed for MEDLINE].
*Stickel F, Seitz HK, Hahn EG, Schuppan D. Medizinische Klinik I und Poliklinik, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol. 1989 Jul;9(1):105-13. PMID: 2671116 [PubMed-indexed for MEDLINE].
*Lucena MI, Andrade RJ, de la Cruz JP, Rodriguez-Mendizabal M, Blanco E, Sanchez de la Cuesta F. Clinical Pharmacology Service, University Hospital, School of Medicine, Malaga, Spain. Effects of silymarin MZ-80 on oxidative stress in patients with alcoholic cirrhosis. Results of a randomized, double-blind, placebo-controlled clinical study. Int J Clin Pharmacol Ther. 2002 Jan;40(1):2-8. PMID: 11841050 [PubMed-indexed for MEDLINE].
*Masini A, Ceccarelli D, Giovannini F, Montosi G, Garuti C, Pietrangelo A. Sezione di Patologia Generale, Dipartimento di Scienze Biomediche Universita di Modena, Italy. Iron-induced oxidant stress leads to irreversible mitochondrial dysfunctions and fibrosis in the liver of chronic iron-dosed gerbils. The effect of silybin. J Bioenerg Biomembr.2000 Apr;32(2):175-82. PMID: 11768750 [PubMed-indexed for MEDLINE].
*Jia JD, Bauer M, Cho JJ, Ruehl M, Milani S, Boigk G, Riecken EO, Schuppan D. Department of Gastroenterology and Hepatology, Friedrich-Alexander University, Erlangen-Nuernberg, Erlangen, Germany. Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen alpha1(I) and TIMP-1. J Hepatol. 2001 Sep;35(3):392-8. PMID: 11592601 [PubMed-indexed for MEDLINE].
*Boigk G, Stroedter L, Herbst H, Waldschmidt J, Riecken EO, Schuppan D. Department of Gastroenterology and Hepatology, Klinikum Benjamin Franklin, Free University of Berlin, Germany. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology. 1997 Sep;26(3):643-9. PMID: 9303494 [PubMed-indexed for MEDLINE].
*Schuppan D, Hahn EG. Clinical studies with silymarin: fibrosis progression is the end point. Hepatology. 2001 Feb;33(2):483-4. PMID: 11172360 [PubMed-indexed for MEDLINE].
*Angulo P, Patel T, Jorgensen RA, Therneau TM, Lindor KD. Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN, USA. Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology. 2000 Nov;32(5):897-900. PMID: 11050036 [PubMed-indexed for MEDLINE].
*Schuppan D, Koda M, Bauer M, Hahn EG. Medizinische Klinik I, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Germany. Fibrosis of liver, pancreas and intestine: common mechanisms and clear targets?. Acta Gastroenterol Belg. 2000 Oct-Dec;63(4):366-70. PMID: 11233519 [PubMed-indexed for MEDLINE].
*Mourelle M, Franco MT. Departamento de Farmacologia y Toxicologia, Centro de Investigacion y de Estudios Avanzados, Instituto Politecnico Nacional, Mexico D.F. Erythrocyte defects precede the onset of CCl4-induced liver cirrhosis. Protection by silymarin. Life Sci. 1991;48(11):1083-90. PMID: 1847733 [PubMed-indexed for MEDLINE].
*Muriel P, Mourelle M. Departamento de Farmacologia y Toxicologia, Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional, Mexico, D.F. The role of membrane composition in ATPase activities of cirrhotic rat liver: effect of silymarin. J Appl Toxicol. 1990 Aug;10(4):281-4. PMID: 2167906 [PubMed-indexed for MEDLINE].
*Lang I, Nekam K, Gonzalez-Cabello R, Muzes G, Gergely P, Feher J. Second Department of Medicine, Semmelweis University Medical School, Budapest, Hungary. Hepatoprotective and immunological effects of antioxidant drugs. Tokai J Exp Clin Med. 1990 May;15(2-3):123-PMID: 1983370 [PubMed-indexed for MEDLINE].
*Kupcova V, Turecky L, Holoman J, Ulicna O, Brixova E, Volmut J. Therapeutic effect of silymarin in patients with liver cirrhosis. Cas Lek Cesk. 1987 Nov 6;126(45):1406-9. PMID: 3427593 [PubMed-indexed for MEDLINE].
*Benda L, Dittrich H, Ferenzi P, Frank H, Wewalka F. The influence of therapy with silymarin on the survival rate of patients with liver cirrhosis (author’s transl). Wien Klin Wochenschr. 1980 Oct 10;92(19):678-83. PMID: 7008367 [PubMed-indexed for MEDLINE].
*Reutter FW, Haase W. Clinical experience with silymarin in the treatment of chronic liver disease(author’s transl). Schweiz Rundsch Med Prax. 1975 Sep 9;64(36):1145-51. PMID: 1099576 [PubMed-indexed for MEDLINE].
*Benda L, Zenz W. Silymarin in liver cirrhosis. Wien Med Wochenschr. 1973 Sep 1;123(3):512-6. PMID: 4748151 [PubMed- indexed for MEDLINE].
*Pares A, Planas R, Torres M, Caballeria J, Viver JM, Acero D, Panes J, Rigau J, Santos J, Rodes J. Hospital Clinic i Provincial, University of Barcelona, Spain. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J Hepatol. 1998 Apr;28(4):615-21. PMID: 9566830 [PubMed-indexed for MEDLINE].
*Stickel F, Seitz HK, Hahn EG, Schuppan D. Medizinische Klinik I und Poliklinik, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen. Alcoholic liver disease–established treatment and new therapeutic approaches. Z Gastroenterol. 2003 Apr;41(4):333-42. PMID: 12695940 [PubMed-indexed for MEDLINE].
*Bunout D, Hirsch S, Petermann M, de la Maza MP, Silva G, Kelly M, Ugarte G, Iturriaga H. Instituto de la Nutricion y Tecnologia de Alimentos (INTA), Facultad de Medicina, Universidad de Chile. Controlled study of the effect of silymarin on alcoholic liver disease. Rev Med Chil. 1992 Dec;120(12):1370-5. PMID: 1343377 [PubMed-indexed for MEDLINE].
*Batakov EA. Pharmacology Department, General Surgery Department, Samara State Medical University, Chapaevskaya ul. 89, Samara, 443099 Russia. Effect of Silybum marianum oil and legalon on lipid peroxidation and liver antioxidant systems in rats intoxicated with carbon tetrachloride. Eksp Klin Farmakol. 2001 Jul-Aug;64(4):53-5. PMID:11589112 [PubMed-indexed for MEDLINE].
*Kravchenko LV, Avren’eva LI, Tutel’ian VA. Effects of bioflavonoids on the toxicity of T-toxin in rats. A biochemical study. Vopr Pitan. 2000;69(5):20-3. PMID: 11247160 [PubMed-indexed for MEDLINE].
*Paulova J, Dvorak M, Kolouch F, Vanova L, Janeckova L. Vyzkumny ustav pro biofaktory a veterinarni leciva, Pohori-Chotoun. Verification of the hepatoprotective and therapeutic effect of silymarin in experimental liver injury with tetrachloromethane in dogs. Vet Med (Praha). 1990 Oct;35(10):629-35. PMID: 2102576 [PubMed-indexed for MEDLINE].
*Sonnenbichler J, Scalera F, Sonnenbichler I, Weyhenmeyer R. Max Planck Institute for Biochemistry, Martinsried, Germany. Stimulatory effects of silibinin and silicristin from the milk thistle Silybum marianum on kidney cells. J Pharmacol Exp Ther. 1999 Sep;290(3):1375-83. PMID: 10454517 [PubMed-indexed for MEDLINE].
*Thamsborg SM, Jorgensen, Brummerstedt E, Bjerregard J. Department of Clinical Studies, Royal Veterinary and Agricultural University, Frederiksberg, Denmark. Putative effect of silymarin on sawfly (Arge pullata)-induced hepatotoxicosis in sheep. Vet Hum Toxicol. 1996 Apr;38(2):89-91. PMID: 8693692 [PubMed-indexed for MEDLINE].
*Porokhniak LA, Drogovoz SM, Rogozhin BA. Action of hepatoprotective agents in a tetracycline lesion of the liver. Antibiot Med Biotekhnol. 1987 Apr;32(4):282-5. PMID: 3631934 [PubMed-indexed for MEDLINE].
*Dwivedi Y, Rastogi R, Sharma SK, Garg NK, Dhawan BN. ICMR Centre for Advanced Pharmacological Research on Traditional Remedies, Central Drug Research Institute, Lucknow, India. Picroliv affords protection against thioacetamide-induced hepatic damage in rats. Planta Med. 1991 Feb;57(1):25-8. PMID: 2062953 [PubMed-indexed for MEDLINE].
*Mereish KA, Bunner DL, Ragland DR, Creasia DA. Medical Division, U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702-5011. Protection against microcystin-LR-induced hepatotoxicity by Silymarin: biochemistry, histopathology, and lethality. Pharm Res. 1991 Feb;8(2):273-7. PMID:1902564 [PubMed-indexed for MEDLINE].
*Muriel P, Garciapina T, Perez-Alvarez V, Mourelle M. Departamento de Farmacologia y Toxicologia, Instituto Politecnico Nacional, Mexico D.F. Silymarin protects against paracetamol-induced lipid peroxidation and liver damage. J Appl Toxicol. 1992 Dec;12(6):439-PMID: 1360480 [PubMed-indexed for MEDLINE].
*Chander R, Kapoor NK, Dhawan BN. Hepatoprotective activity of silymarin against hepatic damage in Mastomys natalensis infected with Plasmodium berghei. Indian J Med Res. 1989 Dec;90:472-7. PMID: 2697691 [PubMed-indexed for MEDLINE].
*Meroni PL, Barcellini W, Borghi MO, Vismara A, Ferraro G, Ciani D, Zanussi C. Institute of Internal Medicine, Infectious Diseases and Immunopathology, University of Milan, Italy. Silybin inhibition of human T- lymphocyte activation. Int J Tissue React. 1988;10(3):177-81. PMID: 3265704 [PubMed-indexed for MEDLINE].
*Boari C, Montanari FM, Galletti GP, Rizzoli D, Baldi E, Caudarella R, Gennari P. Toxic occupational liver diseases. Therapeutic effects of silymarin. Minerva Med. 1981 Oct 20;72(40):2679-88. PMID: 7290471 [PubMed-indexed for MEDLINE].
*Sonnenbichler J, Mattersberger J, Rosen H. Stimulation of RNA synthesis in rat liver and isolated hepatocytes by silybin, an antihepatotoxic agent from Silybum marianum L. Gaertn (author’s transl). Hoppe Seylers Z Physiol Chem. 1976 Aug;357(8):1171-80. PMID: 976944 [PubMed-indexed for MEDLINE].
*He Q, Kim J, Sharma RP. Department of Physiology and Pharmacology, College of Veterinary Medicine, The University of Georgia, Athens, Georgia 30602-7389. Silymarin Protects Against Liver Damage in BALB/c Mice Exposed to Fumonisin B1 Despite Increasing Accumulation of Free Sphingoid Bases. Toxicol Sci. 2004 Apr 21 [Epub ahead of print]. PMID: 15103051 [PubMed-as supplied by publisher].
*Pari L, Murugavel P. Department of Biochemistry, Faculty of Science, Annamalai University, Annamalai Nagar, Tamil Nadu 608 002, India. Protective effect of alpha-lipoic acid against chloroquine-induced hepatotoxicity in rats. J Appl Toxicol. 2004 Jan-Feb;24(1):21-6. PMID: 14745843 [PubMed-in process].
*Rastogi R, Srivastava AK, Rastogi AK. Division of Biochemistry, Central Drug Research Institute, Lucknow-226 001, India. Long term effect of aflatoxin B(1) on lipid peroxidation in rat liver and kidney: effect of picroliv and silymarin. Phytother Res. 2001 Jun;15(4):307-10. PMID: 11406853 [PubMed-indexed for MEDLINE].
*Tuchweber B, Trost W, Salas M, Sieck R. Prevention of praseodymium-induced hepatotoxicity by silybin. Toxicol Appl Pharmacol. 1976 Dec;38(3):559-70. PMID: 1014013 [PubMed-indexed for MEDLINE].
*Szilard S, Szentgyorgyi D, Demeter I. Tisza Chemical Works Leninvaros, Occupational Health Care Service, Hungary. Protective effect of Legalon in workers exposed to organic solvents. Acta Med Hung. 1988;45(2):249-56. PMID: 3073356 [PubMed-indexed for MEDLINE].
*Rastogi R, Srivastava AK, Srivastava M, Rastogi AK. Division of Biochemistry, CDRI, Lucknow. Hepatocurative effect of picroliv and silymarin against aflatoxin B1 induced hepatotoxicity in rats. Planta Med.2000 Dec;66(8):709-13. PMID: 11199126 [PubMed-indexed for MEDLINE].
*Rastogi R, Srivastava AK, Rastogi AK. Division of Biochemistry, Central Drug Research Institute, Lucknow, India. Biochemical changes induced in liver and serum of aflatoxin B1-treated male wistar rats: preventive effect of picroliv. Pharmacol Toxicol. 2001 Feb;88(2):53-8. PMID: 11169162 [PubMed-indexed for MEDLINE].
*Kang JS, Jeon YJ, Park SK, Yang KH, Kim HM. Korea Research Institute of Bioscience and Biotechnology, Taejon, South Korea. Protection against lipopolysaccharide-induced sepsis and inhibition of interleukin-1beta and prostaglandin E2 synthesis by silymarin. Biochem Pharmacol. 2004 Jan 1;67(1):175-81. PMID: 14667940 [PubMed-indexed for MEDLINE].
* Vogel VG, Trost W. Anti-phalloidine activity of the silymarins silybine and disilybine. Arzneimittelforschung. 1975 Mar;25(3):392-3. PMID: 1174039 [PubMed-indexed for MEDLINE].
*Desplaces A, Choppin J, Vogel G, Trost W. The effects of silymarin on experimental phalloidine poisoning. Arzneimittelforschung. 1975 Jan;25(1):89-96. PMID: 125090 [PubMed-indexed for MEDLINE].
*Vogel G, Trost W. Proceedings: Neutralization of the lethal effects of phalloidine and alpha-amanitine in animal experiments by substances from the seeds of Silybum marianum l. Gaertn. Naunyn Schmiedebergs Arch Pharmacol. 1974 Mar 22;282(0):suppl 282:R102. PMID: 4276667 [PubMed-indexed for MEDLINE].
*Wellington K, Jarvis B. Adis International Limited, Auckland, New Zealand. Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs. 2001;15(7):465-89. PMID: 11520257 [PubMed-indexed for MEDLINE].
*Tuchweber B, Sieck R, Trost W. Prevention of silybin of phalloidin-induced acute hepatoxicity. Toxicol Appl Pharmacol. 1979 Nov;51(2):265-75. PMID: 531892 [PubMed-indexed for MEDLINE].
*Schleufe P, Seidel C. Zentrum Anasthesiologie, Abteilung II (Oststadt-Krankenhaus) der Medizinischen Hochschule Hannover. Amanita poisoning during pregnancy. Anasthesiol Intensivmed Notfallmed Schmerzther. 2003 Nov;38(11):716-8. PMID: 14600862 [PubMed-indexed for MEDLINE].
*Faulstich H, Jahn W, Wieland T. Silybin inhibition of amatoxin uptake in the perfused rat liver. Arzneimittelforschung. 1980;30(3):452-4. PMID: 7387753 [PubMed-indexed for MEDLINE].
*Dehmlow C, Erhard J, de Groot H. Institut fur Physiologische Chemie, Universitatsklinikum, Essen, Germany. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology. 1996 Apr;23(4):749-54. PMID: 8666328 [PubMed-indexed for MEDLINE].
*Crocenzi FA, Mottino AD, Roma MG. Instituto de Fisiologia Experimental, CONICET – Universidad Nacional de Rosario, Rosario, Argentina. Regulation of synthesis and trafficking of canalicular transporters and its alteration in acquired hepatocellular cholestasis. Experimental therapeutic strategies for its prevention. Curr Med Chem. 2004 Feb;11(4):501-24. PMID: 14965230 [PubMed-in process].
*Matzkies F, Webs B. Effect of a plant extract combination preparation on gastrointestinal transit time and bile acid excretion. Fortschr Med. 1983 Jul 28;101(27-28):1304-6. PMID: 6618384 [PubMed- indexed for MEDLINE].
*Schandalik R, Gatti G, Perucca E. Surgical Department, Regional Hospital, Braunau am Inn, Austria. Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients. Arzneimittelforschung. 1992 Jul;42(7):964-8. PMID: 1329780 [PubMed-indexed for MEDLINE].
*Skottova N, Krecman V. Institute of Medical Chemistry, Medical Faculty, Palacky University, Olomouc, Czech Republic. Silymarin as a potential hypocholesterolaemic drug. Physiol Res. 1998;47(1):1-7. PMID: 9708694 [PubMed-indexed for MEDLINE].
*Skottova N, Krecman V, Walterova D, Ulrichova J, Kosina P, Simanek V. Institute of Medical Chemistry, Medical Faculty, Palacky University, Olomouc, Czech Republic. Effect of silymarin on serum cholesterol levels in rats. Acta Univ Palacki Olomuc Fac Med.1998;141:87-9. PMID: 9684492 [PubMed-indexed for MEDLINE].
*Krecman V, Skottova N, Walterova D, Ulrichova J, Simanek V. Institute of Medical Chemistry, Medical Faculty, Palacky University, Olomouc, Czech Republic. Silymarin inhibits the development of diet- induced hypercholesterolemia in rats. Planta Med. 1998 Mar;64(2):138- PMID: 9525106 [PubMed-indexed for MEDLINE].
*Nassuato G, Iemmolo RM, Strazzabosco M, Lirussi F, Deana R, Francesconi MA, Muraca M, Passera D, Fragasso A, Orlando R, et al. Istituto di Medicina Interna, Universita di Padova, Italy. Effect of Silibinin on biliary lipid composition. Experimental and clinical study. J Hepatol. 1991 May;12(3):290-5. PMID: 1940257 [PubMed-indexed for MEDLINE].
*Lee DG, Kim HK, Park Y, Park SC, Woo ER, Jeong HG, Hahm KS. Research Center for Proteineous Materials, Chosun University, Korea. Gram-positive bacteria specific properties of silybin derived from Silybum marianum. Arch Pharm Res. 2003 Aug;26(8):597-600. PMID: 12967193 [PubMed-indexed for MEDLINE].
*Kim DH, Jin YH, Park JB, Kobashi K. College of Pharmacy, Kyunghee University, Seoul, Korea. Silymarin and its components are inhibitors of beta-glucuronidase. Biol Pharm Bull. 1994 Mar;17(3):443-5. PMID: 8019514 [PubMed-indexed for MEDLINE].
*Velussi M, Cernigoi AM, De Monte A, Dapas F, Caffau C, Zilli M. Anti-Diabetes Centre, Monfalcone Hospital, Gorizia, Italy. Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J Hepatol. 1997 Apr;26(4):871-9. PMID:9126802 [PubMed-indexed for MEDLINE].
*Skottova N, Kazdova L, Oliyarnyk O, Vecera R, Sobolova L, Ulrichova J. Institute of Pharmacology, Medical Faculty, Palacky University, Hnevotinska 3, 775 15 Olomouc, Czech Republic. Phenolics- rich extracts from Silybum marianum and Prunella vulgaris reduce a high- sucrose diet induced oxidative stress in hereditary hypertriglyceridemic rats. Pharmacol Res. 2004 Aug;50(2):123-30. PMID: 15177299 [PubMed- in process].
*Maghrani M, Zeggwagh NA, Lemhadri A, El Amraoui M, Michel JB, Eddouks M. UFR PNPE, BP 21, Errachidia 52000, Morocco. Study of the hypoglycaemic activity of Fraxinus excelsior and Silybum marianum in an animal model of type 1 diabetes mellitus. J Ethnopharmacol. 2004 Apr;91(2-3):309-16. PMID: 15120454 [PubMed-in process].
*Savickiene N, Dagilyte A, Lukosius A, Zitkevicius V. Kauno medicinos universiteto Farmacines chemijos ir farmakognozijos katedra, A. Mickeviciaus 9, 3000 Kaunas. Importance of biologically active components and plants in the prevention of complications of diabetes mellitus. Medicina (Kaunas). 2002;38(10):970-5. PMID: 12532704 [PubMed-indexed for MEDLINE].
*Geller LI, Gladkikh LN, Griaznova MV. Treatment of fatty hepatosis in diabetics. Probl Endokrinol (Mosk). 1993 Sep-Oct;39(5):20-2. PMID: 8108340 [PubMed-indexed for MEDLINE].
*Kelly GS. Insulin resistance: lifestyle and nutritional interventions. Altern Med Rev. 2000 Apr;5(2):109-32. PMID: 10767668 [PubMed- indexed for MEDLINE].
*Feher J, Lengyel G, Blazovics A. National Institute of Internal Medicine, 2nd Dept. of Medicine, Semmelweis University, Budapest, Hungary. Oxidative stress in the liver and biliary tract diseases. Scand J Gastroenterol Suppl. 1998;228:38-46. PMID: 9867111 [PubMed-indexed for MEDLINE].
*Feher J, Lang I, Nekam K, Gergely P, Muzes G. Second Department of Medicine, Semmelweis University Medical School, Budapest, Hungary. In vivo effect of free radical scavenger hepatoprotective agents on superoxide dismutase (SOD) activity in patients. Tokai J Exp Clin Med. 1990 May;15(2-3):129-34. PMID: 2130521 [PubMed-indexed for MEDLINE].
*Feher J, Lang I, Nekam K, Muzes G, Deak G. Second Department of Medicine, Semmelweis University Medical School, Budapest, Hungary. Effect of free radical scavengers on superoxide dismutase (SOD) enzyme in patients with alcoholic cirrhosis. Acta Med Hung. 1988;45(3-4):265-76. PMID: 3249654 [PubMed-indexed for MEDLINE].
*Muzes G, Deak G, Lang I, Nekam K, Niederland V, Feher J. Semmelweis Orvostudomanyi Egyetem, II. Belgyogyaszati Klinika, Budapest. Effect of silimarin (Legalon) therapy on the antioxidant defense mechanism and lipid peroxidation in alcoholic liver disease (double blind protocol). Orv Hetil. 1990 Apr 22;131(16):863-6. PMID: 2345633 [PubMed-indexed for MEDLINE].
*Feher J, Lang I, Nekam K, Csomos G, Muzes G, Deak G. Second Department of Medicine, Semmelweis University Medical School, Budapest, Hungary. Effect of silibinin on the activity and expression of superoxide dismutase in lymphocytes from patients with chronic alcoholic liver disease. Free Radic Res Commun. 1987;3(6):373-7. PMID: 3508451 [PubMed-indexed for MEDLINE].
*Varga Z, Ujhelyi L, Kiss A, Balla J, Czompa A, Antus S. Ist Department of Medicine, Medical and Health Science Centre, Debrecen, Hungary. Effect of silybin on phorbol myristate actetate-induced protein kinase C translocation, NADPH oxidase activity and apoptosis in human neutrophils. Phytomedicine. 2004 Feb;11(2-3):206-12. PMID: 15070174 [PubMed-indexed for MEDLINE]
*Griemel A, Koch H. Peroxidase isoenzymes in silybum marianum (author’s transl). Planta Med. 1977 Dec;32(4):323-30. PMID: 594206 [PubMed-indexed for MEDLINE].
*Gebhardt R. Institute of Biochemistry, Medical Faculty, University of Leipzig, Leipzig, Germany. Antioxidative, antiproliferative and biochemical effects in HepG2 cells of a homeopathic remedy and its constituent plant tinctures tested separately or in combination. Arzneimittelforschung. 2003;53(12):823-30. PMID: 14732962 [PubMed- indexed for MEDLINE].
*Soto C, Recoba R, Barron H, Alvarez C, Favari L. Departamento de Sistemas Biologicos, Universidad Autonoma Metropolitana- Xochimilco. Calzada del Hueso 1100, Col. Villa Quietud, DF CP 04960, Mexico. Silymarin increases antioxidant enzymes in alloxan-induced diabetes in rat pancreas. Comp Biochem Physiol C Toxicol Pharmacol. 2003 Nov;136(3):205-12. PMID: 14659454 [PubMed-in process].
*Chlopcikova S, Psotova J, Miketova P, Simanek V. Institute of Medical Chemistry and Biochemistry, Faculty of Medicine, Hnevotinska 3, 775 15 Olomouc, Czech Republic. Chemoprotective effect of plant phenolics against anthracycline-induced toxicity on rat cardiomyocytes. Part I. Silymarin and its flavonolignans. Phytother Res. 2004 Feb;18(2):107-10. PMID: 15022159 [PubMed-indexed for MEDLINE].
*Svagera Z, Skottova N, Vana P, Vecera R, Urbanek K, Belejova M, Kosina P, Simanek V. Institute of Medical Chemistry, Palacky University, Olomouc, Czech Republic. Plasma lipoproteins in transport of silibinin, an antioxidant flavonolignan from Silybum marianum. Phytother Res. 2003 May;17(5):524-30. PMID: 12748991 [PubMed-indexed for MEDLINE].
*Johnson VJ, Osuchowski MF, He Q, Sharma RP. Department of Physiology and Pharmacology, College of Veterinary Medicine, The University of Georgia, Athens, GA 30602-7389, USA. Physiological responses to a natural antioxidant flavonoid mixture, silymarin, in BALB/c mice: II. alterations in thymic differentiation correlate with changes in c- myc gene expression. Planta Med. 2002 Nov;68(11):961-5. PMID: 12451483 [PubMed-indexed for MEDLINE].
*Lang I, Deak G, Muzes G, Pronai L, Feher J. Second Department of Medicine, Semmelweis University, Budapest, Hungary. Effect of the natural bioflavonoid antioxidant silymarin on superoxide dismutase (SOD) activity and expression in vitro. Biotechnol Ther. 1993;4(3-4):263-70. PMID: 8292974 [PubMed-indexed for MEDLINE].
*He Q, Osuchowski MF, Johnson VJ, Sharma RP. Department of Physiology and Pharmacology, College of Veterinary Medicine, The University of Georgia, Athens, GA 30602-7389, USA. Physiological responses to a natural antioxidant flavonoid mixture, silymarin, in BALB/c mice: I induction of transforming growth factor beta1 and c-myc in liver with marginal effects on other genes. Planta Med. 2002 Aug;68(8):676-9. PMID: 12221586 [PubMed-indexed for MEDLINE].
*Varga Z, Czompa A, Kakuk G, Antus S. First Department of Medicine, University Medical School, 4012 Debrecen, Nagyerdei krt. 98. P.O. Box 19, Hungary. Inhibition of the superoxide anion release and hydrogen peroxide formation in PMNLs by flavonolignans. Phytother Res. 2001 Nov;15(7):608-12. PMID: 11746843 [PubMed-indexed for MEDLINE].
*Loginov AS, Matiushin BN, Sukhareva GV, Tkachev VD. Antioxidant activity of hepatotropic preparations in the treatment of chronic diseases of the liver. Ter Arkh. 1988;60(8):74-7. PMID: 3227482 [PubMed-indexed for MEDLINE].
*Skottova N, SVagera Z, Vecera R, Urbanek K, Jegorov A, Simanek V. Institute of Pharmacology, Medical Faculty, Palacky University, Olomouc, Czech Republic. Pharmacokinetic study of iodine- labeled silibinins in rat. Pharmacol Res. 2001 Sep;44(3):247-53. PMID: 11529693 [PubMed-indexed for MEDLINE].
*Skottova N, Krecman V, Simanek V. Institute of Medical Chemistry, Medical Faculty, Palacky University, Hnevotinska 3, 775 15 Olomouc, Czech Republic. Activities of silymarin and its flavonolignans upon low density lipoprotein oxidizability in vitro. Phytother Res. 1999 Sep;13(6):535-7. PMID: 10479770 [PubMed-indexed for MEDLINE].
*Bosisio E, Benelli C, Pirola O. Institute of Pharmacological Sciences, Faculty of Pharmacy, University of Milan, Italy. Effect of the flavanolignans of Silybum marianum L. on lipid peroxidation in rat liver microsomes and freshly isolated hepatocytes. Pharmacol Res. 1992 Feb- Mar;25(2):147-54. PMID: 1635893 [PubMed-indexed for MEDLINE].
*Valenzuela A, Aspillaga M, Vial S, Guerra R. Selectivity of silymarin on the increase of the glutathione content in different tissues of the rat. Planta Med. 1989 Oct;55(5):420-2. PMID: 2813578 [PubMed- indexed for MEDLINE].
*Koch HP, Bachner J, Loffler E. Silymarin: potent inhibitor of cyclic AMP phosphodiesterase. Methods Find Exp Clin Pharmacol. 1985 Aug;7(8):409-13. PMID: 3001454 [PubMed-indexed for MEDLINE].
*Psotova J, Chlopcikova S, Grambal F, Simanek V, Ulrichova J. Institute of Medical Chemistry and Biochemistry, Faculty of Medicine, Palacky University, Hnevotinska 3, 775 15 Olomouc, Czech Republic. Influence of silymarin and its flavonolignans on doxorubicin-iron induced lipid peroxidation in rat heart microsomes and mitochondria in comparison with quercetin. Phytother Res. 2002 Mar;16 Suppl 1:S63-7. PMID:11933142 [PubMed-indexed for MEDLINE].
*Johnson VJ, He Q, Osuchowski MF, Sharma RP. Department of Physiology and Pharmacology, College of Veterinary Medicine, The University of Georgia, Athens, GA 30602-7389, USA. Physiological responses of a natural antioxidant flavonoid mixture, silymarin, in BALB/c mice: III. Silymarin inhibits T-lymphocyte function at low doses but stimulates inflammatory processes at high doses. Planta Med. 2003 Jan;69(1):44-9. PMID: 12567278 [PubMed-indexed for MEDLINE].
*Gupta OP, Sing S, Bani S, Sharma N, Malhotra S, Gupta BD, Banerjee SK, Handa SS. Regional Research Laboratory (CSIR) Jammu Tawi, India. Anti-inflammatory and anti-arthritic activities of silymarin acting through inhibition of 5-lipoxygenase. Phytomedicine. 2000 Mar;7(1):21-4. PMID: 10782486 [PubMed-indexed for MEDLINE].
*Wilasrusmee C, Kittur S, Shah G, Siddiqui J, Bruch D, Wilasrusmee S, Kittur DS. Department of Surgery SUNY Upstate Medical University, Syracuse, New York 13210, USA. Immunostimulatory effect of Silybum Marianum (milk thistle) extract. Med Sci Monit. 2002 Nov;8(11):BR439-43. PMID: 12444368 [PubMed-indexed for MEDLINE].
*Wilasrusmee C, Siddiqui J, Bruch D, Wilasrusmee S, Kittur S, Kittur DS. Department of Surgery, SUNY Upstate Medical University, Syracuse, New York 13210, USA. In vitro immunomodulatory effects of herbal products. Am Surg. 2002 Oct;68(10):860-4. PMID: 12412711 [PubMed-indexed for MEDLINE].
*Amirghofran Z, Azadbakht M, Karimi MH. Immunology Department, Medical School, Shiraz University of Medical Sciences, PO BOX 71345-1798, Shiraz, Iran. Evaluation of the immunomodulatory effects of five herbal plants. J Ethnopharmacol. 2000 Sep;72(1-2):167-72. PMID: 10967468 [PubMed-indexed for MEDLINE].
*Kalmar L, Kadar J, Somogyi A, Gergely P, Csomos G, Feher J. Second Department of Medicine, Semmelweis University, Budapest, Hungary. Silibinin (Legalon-70) enhances the motility of human neutrophils immobilized by formyl-tripeptide, calcium ionophore, lymphokine and by normal human serum. Agents Actions. 1990 Mar;29(3-4):239-46. PMID: 2111081 [PubMed-indexed for MEDLINE].
*Kittur S, Wilasrusmee S, Pedersen WA, Mattson MP, Straube- West K, Wilasrusmee C, Lubelt B, Kittur DS. Department of Neurology, SUNY Upstate Medical University, Syracuse, NY 13210, USA. Neurotrophic and neuroprotective effects of milk thistle (Silybum marianum) on neurons in culture. J Mol Neurosci. 2002 Jun;18(3):265-9. PMID: 12059045 [PubMed-indexed for MEDLINE].
*Wang MJ, Lin WW, Chen HL, Chang YH, Ou HC, Kuo JS, Hong JS, Jeng KC. Department of Education and Research, Taichung Veterans General Hospital, Taichung 40705, Taiwan. Silymarin protects dopaminergic neurons against lipopolysaccharide-induced neurotoxicity by inhibiting microglia activation. Eur J Neurosci. 2002 Dec;16(11):2103-PMID: 12473078 [PubMed-indexed for MEDLINE].
*Thelen P, Jarry H, Ringert RH, Wuttke W. Department of Urology, Georg-August-University, Gottingen, Germany. Silibinin down-regulates prostate epithelium-derived Ets transcription factor in LNCaP prostate cancer cells. Planta Med. 2004 May;70(5):397-400. PMID: 15124082 [PubMed-in process].
*Thelen P, Wuttke W, Jarry H, Grzmil M, Ringert RH. Department of Urology, Institute of Human Genetics, Georg-August-University, Gottingen, Germany. Inhibition of telomerase activity and secretion of prostate specific antigen by silibinin in prostate cancer cells. J Urol. 2004 May;171(5):1934-8. PMID: 15076315 [PubMed-indexed for MEDLINE].
*Hannay JA, Yu D. The University of Texas, M.D. Anderson Cancer Center; Houston, Texas USA. Silibinin: a thorny therapeutic for EGF-R expressing tumors?. Cancer Biol Ther. 2003 Sep-Oct;2(5):532-3. PMID: 14614321 [PubMed-indexed for MEDLINE].
*Dhanalakshmi S, Agarwal P, Glode LM, Agarwal R. Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Health Sciences Center, Denver, CO 80262, USA. Silibinin sensitizes human prostate carcinoma DU145 cells to cisplatin- and carboplatin- induced growth inhibition and apoptotic death. Int J Cancer. 2003 Sep 20;106(5):699-705. PMID: 12866029 [PubMed-indexed for MEDLINE].
*Ladas EJ, Kelly KM. Division of Pediatric Oncology, Columbia University, New York, NY, USA. Milk thistle: is there a role for its use as an adjunct therapy in patients with cancer?. J Altern Complement Med. 2003 Jun;9(3):411-6. PMID: 12816629 [PubMed-indexed for MEDLINE].
*Tyagi A, Bhatia N, Condon MS, Bosland MC, Agarwal C, Agarwal R. Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA. Antiproliferative and apoptotic effects of silibinin in rat prostate cancer cells. Prostate. 2002 Nov 1;53(3):211-7. PMID: 12386921 [PubMed-indexed for MEDLINE].
*Kohno H, Tanaka T, Kawabata K, Hirose Y, Sugie S, Tsuda H, Mori H. First Department of Pathology, Kanazawa Medical University, Ishikawa, Japan. Silymarin, a naturally occurring polyphenolic antioxidant flavonoid, inhibits azoxymethane-induced colon carcinogenesis in male F344 rats. Int J Cancer. 2002 Oct 10;101(5):461-8. PMID: 12216075 [PubMed-indexed for MEDLINE].
*Yanaida Y, Kohno H, Yoshida K, Hirose Y, Yamada Y, Mori H, Tanaka T. Department of Laboratory Sciences, School of Health Sciences, Faculty of Medicine, Kanazawa University, 5-11-80 Kodatsuno, Kanazawa 920-0942, Japan. Dietary silymarin suppresses 4- nitroquinoline 1-oxide-induced tongue carcinogenesis in male F344 rats. Carcinogenesis. 2002 May;23(5):787-94. PMID: 12016151 [PubMed- indexed for MEDLINE].
*Manna SK, Mukhopadhyay A, Van NT, Aggarwal BB. Department of Molecular Oncology, Cytokine Research Laboratory, University of Texas M. D. Anderson Cancer Center, Houston 77030, USA. Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis. J Immunol. 1999 Dec 15;163(12):6800-9. PMID: 10586080 [PubMed-indexed for MEDLINE].
*Singh RP, Agarwal R. Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Cancer Center, 4200 East Ninth Avenue, Denver, CO 80262, USA. Prostate cancer prevention by silibinin. Curr Cancer Drug Targets. 2004 Feb;4(1):1-11. PMID: 14965263 [PubMed-in process].
*Kang SN, Lee MH, Kim KM, Cho D, Kim TS. College of Pharmacy, Chonnam National University, Kwangju 500-757, Republic of Korea. Induction of human promyelocytic leukemia HL-60 cell differentiation into monocytes by silibinin: involvement of protein kinase C. Biochem Pharmacol. 2001 Jun 15;61(12):1487-95. PMID: 11377378 [PubMed-indexed for MEDLINE].
*Neese S, La Grange L, Trujillo E, Romero D. Department of Behavioral Sciences, New Mexico Highlands University, 117 Hewett Hall, Las Vegas, NM 87701, USA. The effects of ethanol and silymarin treatment during gestation on spatial working memory. BMC Complement Altern Med. 2004 Feb 12;4(1):4. PMID: 15018621 [PubMed-in process]. * Reid C, Edwards J, Wang M, Manybeads Y, Mike L, Martinez N, La Grange L, Reyes E. Department of Behavioral Sciences, New Mexico Highlands University, Las Vegas, USA. Prevention by a silymarin/phospholipid compound of ethanol-induced social learning deficits in rats. Planta Med. 1999 Jun;65(5):421-4. PMID: 10418328 [PubMed-indexed for MEDLINE].
*La Grange L, Wang M, Watkins R, Ortiz D, Sanchez ME, Konst J, Lee C, Reyes E. New Mexico Highlands University, Las Vegas 87701, USA. Protective effects of the flavonoid mixture, silymarin, on fetal rat brain and liver. J Ethnopharmacol. 1999 Apr;65(1):53-61. PMID: 10350368 [PubMed-indexed for MEDLINE].
*Giannola C, Buogo F, Forestiere G, Scaffidi L, Ferrigno V, Scaffidi A. A two-center study on the effects of silymarin in pregnant women and adult patients with so-called minor hepatic insufficiency. Clin Ter. 1985 Jul 31;114(2):129-35. PMID: 4053531 [PubMed-indexed for MEDLINE].
*Zuber R, Modriansky M, Dvorak Z, Rohovsky P, Ulrichova J, Simanek V, Anzenbacher P. Faculty of Chemical Technology, University of Pardubice, Nam. Cs. Legii 565, 532 10 Pardubice, Czech Republic. Effect of silybin and its congeners on human liver microsomal cytochrome P450 activities. Phytother Res. 2002 Nov;16(7):632-8. PMID: 12410543 [PubMed-indexed for MEDLINE].
*Beckmann-Knopp S, Rietbrock S, Weyhenmeyer R, Bocker RH, Beckurts KT, Lang W, Hunz M, Fuhr U. Institute for Pharmacology, Clinical Pharmacology, University of Koln, Germany. Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes. Pharmacol Toxicol. 2000 Jun;86(6):250-6. PMID: 10895987 [PubMed- indexed for MEDLINE].
*No authors listed. Toxicity. Milk thistle and indinavir. Treatmentupdate. 2002 Sep-Oct;14(7):4-5. PMID: 12400499 [PubMed- indexed for MEDLINE].
*Rajnarayana K, Reddy MS, Vidyasagar J, Krishna DR. Drug Metabolism and Clinical Pharmacokinetics Division, University College of Pharmceutical Sciences, Kakatiya University, Warangal, AP, India. Study on the influence of silymarin pretreatment on metabolism and disposition of metronidazole. Arzneimittelforschung. 2004;54(2):109-13. PMID: 15038460 [PubMed-indexed for MEDLINE].
*Mourelle M, Favari L. Departmento de Farmacologia y Toxicologia, Centro de Investigacion y de Estudios Avanzados del I.P.N., Mexico, D.F. Silymarin improves metabolism and disposition of aspirin in cirrhotic rats. Life Sci. 1988;43(3):201-7. PMID: 3398694 [PubMed- indexed for MEDLINE].
*Palasciano G, Portincasa P, Palmieri V, et al. The effect of silymarin on plasma levels of malon-dialdehyde in patients receiving long- term treatment with psychotropic drugs. Curr Ther Res. 1994;55:537-545.
*Khayyal MT, el-Ghazaly MA, Kenawy SA, Seif-el-Nasr M, Mahran LG, Kafafi YA, Okpanyi SN. Department of Pharmacology, Faculty of Pharmacy, Cairo University, Cairo, Egypt. Antiulcerogenic effect of some gastrointestinally acting plant extracts and their combination. Arzneimittelforschung. 2001;51(7):545-53. PMID: 11505785 [PubMed- indexed for MEDLINE].
*Alarcon de la Lastra AC, Martin MJ, Motilva V, Jimenez M, La Casa C, Lopez A. Departamento de Farmacia y Tecnologia Farmaceutica, Facultad de Farmacia, Sevilla, Spain. Gastroprotection induced by silymarin, the hepatoprotective principle of Silybum marianum in ischemia-reperfusion mucosal injury: role of neutrophils. Planta Med. 1995 Apr;61(2):116-9. PMID: 7753916 [PubMed-indexed for MEDLINE].
*Cruz T, Galvez J, Crespo E, Ocete MA, Zarzuelo A. Effects of silymarin on the acute stage of the trinitrobenzenesulphonic acid model of rat colitis. Planta Med. 2001 Feb;67(1):94-6. PMID: 11270735 [PubMed- indexed for MEDLINE].
*Gil’miiarov EM, Radomskaia VM, Kretova IG, Vinogradova LN, Babichev AV, Ponomareva LA, Samykina LN, Sheshunov IV, Gil’miiarov EM. Biologically active additive from milk thistle in the solution of public health problems. Vopr Pitan. 1998;(3):33-5. PMID: 9752670 [PubMed- indexed for MEDLINE].
*Rui YC. College of Pharmacy, Second Military Medical University, Shanghai, China. Advances in pharmacological studies of silymarin. Mem Inst Oswaldo Cruz. 1991;86 Suppl 2:79-85. PMID: 1842018 [PubMed- indexed for MEDLINE].
*Allain H, Schuck S, Lebreton S, Strenge-Hesse A, Braun W, Gandon JM, Brissot P. Laboratoire de Pharmacologie Experimentale et Clinique, Faculte de Medecine, Universite de Rennes I, Rennes, France. Aminotransferase levels and silymarin in de novo tacrine-treated patients with Alzheimer’s disease. Dement Geriatr Cogn Disord. 1999 May- Jun;10(3):181-5. PMID: 10325444 [PubMed-indexed for MEDLINE].
*L Pitzel, C Castillo Robles, J Tresguerres, S Taubert, V Christoffel, W Wuttke. Effects of estradiol (E2) and some phytoestrogens (PEs) containing plant extracts on differentiated 3T3-L1 fat cells. Exp Clin Endocrinol Diabetes. DOI: 10.1055/s-2004-819223
*No authors listed. An adverse reaction to the herbal medication milk thistle (Silybum marianum). Adverse Drug Reactions Advisory Committee. Med J Aust. 1999 Mar 1;170(5):218-9. PMID: 10092919 [PubMed-indexed for MEDLINE]
*Lee DY, Liu Y. Bio-Organic and Natural Product Laboratory, McLean Hospital/Harvard Medical School, 115 Mill Street, Belmont, Massachusetts 02478, USA. Molecular structure and stereochemistry of silybin A, silybin B, isosilybin A, and isosilybin B, Isolated from Silybum marianum (milk thistle). J Nat Prod. 2003 Sep;66(9):1171-4. Erratum in: J Nat Prod. 2003 Dec;66(12):1632. PMID: 14510591 [PubMed-indexed for MEDLINE].
*Kim NC, Graf TN, Sparacino CM, Wani MC, Wall ME. Natural Product Laboratory, Chemistry and Life Sciences, Research Triangle Institute, 3040 Cornwallis Road, Research Triangle Park, North Carolina 27709, USA. Complete isolation and characterization of silybins and isosilybins from milk thistle (Silybum marianum). Org Biomol Chem. 2003 May 21;1(10):1684-9. Erratum in: Org Biomol Chem. 2003 Oct 7;1(19):3470. PMID: 12926355 [PubMed-indexed for MEDLINE].
*Wallace SN, Carrier DJ, Clausen E. Department of Biological and Agricultural Engineering, University of Arkansas, 203 Engineering Hall, Fayetteville, AR 72701, USA. Extraction of nutraceuticals from milk thistle: part II. Extraction with organic solvents. Appl Biochem Biotechnol. 2003 Spring;105 -108:891-903. PMID: 12721426 [PubMed-indexed for MEDLINE].
*Barreto JF, Wallace SN, Carrier DJ, Clausen EC. Department of Chemical Engineering, University of Arkansas, 3202 Bell Engineering Center, Fayetteville, AR 72701, USA. Extraction of nutraceuticals from milk thistle: I. Hot water extraction. Appl Biochem Biotechnol. 2003 Spring;105 -108:881-9. PMID: 12721425 [PubMed-indexed for MEDLINE].
*Kvasnicka F, Biba B, Sevcik R, Voldrich M, Kratka J. Institute of Chemical Technology, Technicka 3, Prague 6, Czech Republic. Analysis of the active components of silymarin. J Chromatogr A. 2003 Mar 21;990(1-2):239-45. PMID: 12685603 [PubMed-indexed for MEDLINE].
*Gil’miiarova FN, Tutel’ian VA, Radomskaia VM, Gapparov MM, Kuznetsova OIu, Babichev AV, Kretova IG, Vinogradova LN, Baisheva GM, Gil’miliarov EM, Kleiman MS, Gergel’ NI, Vandyshev VV. Biological value of Silybum marianum oil. Vopr Pitan. 2002;71(4):32-5. PMID: 12462953 [PubMed-indexed for MEDLINE].
*Pepping J. Kaiser Permanente, Honolulu, HI, USA. Milk thistle: Silybum marianum. Am J Health Syst Pharm. 1999 Jun 15;56(12):1195-7. PMID: 10484652 [PubMed-indexed for MEDLINE].
*Szentmihalyi K, Kery A, Lakatos B, Sandor Z, Petri G. MTA, Kemiai Kutatokozpont, Kemiai Intezet, Budapest. Determination of 23 elements in lady’s thistle (Silybum marianum L. Gaertner). Acta Pharm Hung. 1998 May;68(3):157-62. PMID: 9703702 [PubMed-indexed for MEDLINE]
*Morelli I. Constituents of Silybum marianum and their therapeutic use. Boll Chim Farm. 1978 May;117(5):258-67. PMID: 743375 [PubMed- indexed for MEDLINE].
*Takemoto T, Ikegawa S, Nomoto K. Studies on constituents of Silybum marianum (L.) Gaertn. I. New flavonolignans named 2,3- dehydrosilymarin and 2,3-dehydrosilychristin. Yakugaku Zasshi. 1975 Aug;95(8):1017-21. PMID: 1237601 [PubMed-indexed for MEDLINE].
*Wagner H, Diesel P, Seitz M. The chemistry and analysis of silymarin from Silybum marianum Gaertn. Arzneimittelforschung. 1974 Apr;24(4):466-71. PMID: 4408125 [PubMed-indexed for MEDLINE].
*Holzl J. Biosynthesis and (14C) labelling of flavonolignans (silymarin) by Silybum marianum (Haller) (author’s transl). Z Naturforsch [C]. 1974 Jan-Feb;29(1):82-3. PMID: 4276432 [PubMed-indexed for MEDLINE].
*Halbach G, Gorler K. Separation of flavonoids from the fruits of St Mary’s distel (Silybum marianum). Planta Med. 1971 Apr;19(4):293-8. PMID: 5573540 [PubMed-indexed for MEDLINE].
*Schulte KE, Rucker G, Stigler H. Polyacetylenes as contents of Silybum marianum Gaertn. Arch Pharm Ber Dtsch Pharm Ges. 1970 Jan;303(1):7-17. PMID: 5265687 [PubMed-indexed for MEDLINE].
*Wagner H, Horhammer L, Seitz M. Chemical evaluation of a silymarin-containing flavonoid concentrate from Silybum marianum (L.) Gaertn. Arzneimittelforschung. 1968 Jun;18(6):696-8. PMID: 5755806 [PubMed-indexed for MEDLINE].
*Morazzoni P, Montalbetti A, Malandrino S, Pifferi G. Inverni della Beffa Research and Development Laboratories, Milan, Italy. Comparative pharmacokinetics of silipide and silymarin in rats. Eur J Drug Metab Pharmacokinet. 1993 Jul-Sep;18(3):289-97. PMID: 8149949 [PubMed- indexed for MEDLINE].
BIBLIOGRAFIJA
- Real Farmacopea Española 2ª Edición (2002).
- Pharmacopée Française IX Édition.
- British Herbal Pharmacopoeia, 1983.
- Herbal Drugs and Phytopharmaceuticals. Norman Grainger Bisset (Ed). Max Wichtl. CRC Press.1994.
- Plantas Medicinales y Drogas Vegetales para infusión y tisana. Edición española a cargo de: Salvador Cañogueral, Roser Vila, Max Wichtl.1998.
- Matière Médicale. RR Paris- H. Moyse. Masson 1981.
- Fitoterapia: Vademecum de Prescripción. Plantas Medicinales. Colaboran: Asociación española de médicos naturistas. Colegio Oficial de Farmacéuticos de Vizcaya.
- Guía de Campo de las Flores de Europa. Oleg Polunin. Edicione
- Omega S.A. Barcelona, 1977.
- Plantas Medicinales. Margarita Fernandez y Ana Nieto. Ed Universidad de Navarra. EUNSA 1982.
- 100 Plantes Medicinales. Max Rombi. Romart 1998.
- Fitoterapia Aplicada. J.B. Peris, G. Stübing, B.Vanaclocha. ColegioOficial de Farmacéuticos de Valencia 1995.
- Pharmacognosy, Phytochemistry, Medicinal Plants. Jean Bruneton. Lavoisier Publishing.
- The Complete German Commission E Monographs. Therapeutic Guide To Herbal Medicines. Mark Blumenthal. American Botanical Council1998.
- Revista de fitoterapia 2000. CITA Publicaciones y Documentación S.L.
- Farmacognosia 2ª Edición. Jean Bruneton. Ediciones Acribia S.A. 2001.
- Pharmacognosy 9th Edition.
- Bulletin officiel Nº 90/22 bis. Ministère des Affaires Sociales et de laSolidarité.
- French Public Health Code.
- Bézanger-Beauquesne, L; Pinkas, M; Torck, M. Les Plantes dans la Therapeutique Moderne. 2ª. Paris: Maloine, 1986.
- Bézanger-Beauquesne, L; Pinkas, M; Torck, M; Trotin, F. Plantes Médicinales des Regions Tempérées. Paris: Maloine, 1980.
- European Scientific Cooperative On Phytotherapy (E.S.C.O.P.). Monographs on the medicinal uses of plant drugs. Fascicle I: Thymi herba. March, 1996.
- James, A; Duke, Ph D. Handbook of Medicinal Herbs. 5ª. Boca Ratón, Florida: CRC Press, 1987, pp.170-1.
- Paris, RR; Moyse, M. Précis de Matière Médicale. Tome III. Paris: Masson, 1971, p. 450.
- Samuelsson, G. Drugs of Natural Origin. A Textbook of Pharmacognosy. Stockholm: Swedish Pharmaceutical Press, 1992, p.123.
- Trease, GE; Evans, WCh. Farmacognosia. México D.F.: Interamericana–MacGraw-Hill, 1991, p. 450.
- Van Hellemont, J. Compendium de Phytotherapie. Bruxelles: Association Pharmaceutique Belge, 1986, pp. 80-1.
- Wichtl, M. Herbal Drugs and Phytopharmaceutical. A Handbook for Practice on a Scientific basis. Stuttgart: Medpharm Scientific Publishers,1994, pp. 121-5.